Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s ...
Supernus: Q4 Earnings Snapshot
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 52 cents per share. The drugmaker posted revenue of $174.2 million in the period, which also beat ...
Supernus reports Q4 EPS 27c, consensus 52c
Reports Q4 revenue $174.2M, consensus $155.25M. “Our 2024 results reflect solid commercial execution across the company, including continued ...
Supernus sees FY25 revenue $600M-$630M, consensus $622.27M
Sees FY25 adjusted operating earnings $105M-$130M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...
Supernus Pharmaceuticals Q4 revenue beats, EPS misses estimates
The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...
pharmaphorum23h
Supernus bulks up its Parkinson's portfolio with Adamas takeover
Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.